Twitter
Facebook
LinkedIn
Instagram
YouTube
Search
Home
Conference News
Archive
2022
January 26
December 7
Industry Programs
Industry Theaters
Guru Bars
Evening Symposia
On-Demand Programs
Preview Edition
Conference Program
Photos
Special Topics
Audio Briefs
REGISTER NOW
CONFERENCE HOME
Innovative trial design: Inhaled imatinib for Pulmonary Arterial Hypertension, design of the phase 2b/3 IMPAHCT study
04/27/2022
Previous:
Why and when is IL-8 inflammation important in COVID-19?
Next:
Nontuberculous Mycobacterial Lung Disease (NTM-LD): Overcoming Common Pitfalls in Diagnosis and Treatment
